

Inhaled drugs - From Disease to First Time in Man

Workshop, June 13, 2024, Lund, Sweden

The development of pulmonary delivered drugs is an area of expertise for the Swedish pharmaceutical industry. This area is still very relevant with new potential indications and can be used for both local and systemic drug delivery.

The purpose of the workshop is to discuss the knowledge and challenges in preclinical development of inhaled drugs and to develop and strengthen the national network of people in the academia and industry active in this area.

This is the second symposium that the SwedIN network has initiated together with MVIC and Apotekarsocieteten.

Who should attend?

The meeting targets people that have an interest or are actively working with research, development, manufacturing and control of inhaled medicines. The meeting also reach out to people that have an interest in Swedish Inhalation Network.

The Swedish Inhalation Network

The Swedish Inhalation Network (SwedIN) is a community of scientists in academia, healthcare and industry united in a common interest in inhaled medicines. The ambition of SwedIN is to create meeting places for scientific dialogues that can stimulate interest in the field, ensure handover of competence to next generation of scientists and provide opportunities for collaboration and scientific advancement.

Organizers

The SwedIN Network together with Medicon Valley Inhalation Consortium (MVIC)

Organizing committee:

Oskar Hallgren, Truly Labs
Anna-Karin Larsson-Callerfelt, Lund University
Per Bäckman, Per Backman Consulting AB
Pär Ewing, AstraZeneca



Details

Date: 2024-06-13

Time: 09:30-16:30

Venue: Medicon Village

Town: Lund

Organizer: SwedIN

Participation fee: SEK: 1600 (excl. VAT), SEK: 800 (excl. VAT) for graduate and undergraduate students.

Registration

[MVIC | SwedIN - Lung Science Workshop 2024](#) (open hyperlink)

Registration is opened until June 3rd. Students should contact oskar@Trulylabs.com to get a discount code.

	Speaker	Subject
1.	Lung diseases/Pathophysiology	Göran Tornling, Karolinska Institutet
2.	PK/PD, PKPD and TE models	Karin von Wachenfeldt, Truly Labs
3.	New Modalities for inhaled drugs	Martin Hemmerlin, AstraZeneca
4.	Safety assessment for inhaled drugs	Anna Steneholm, TKT
5.	Critical in vitro attributes- deposition, dissolution and permeation	Sabrina Valetti, Malmö University
6.	Regional targeting for inhaled drugs	Per Gerde, Inhalation Sciences Sweden AB
7.	Regulatory challenges in registration of inhaled drugs.	Mikael Ekström, Iconovo
8.	Panel Discussion: Future challenges and opportunities?	All speakers

Questions:

If you have questions about the workshop, contact oskar@Trulylabs.com

